9 ± 16.1 143.5 ± 14.0 140.0 ± 13.0 138.5 ± 12.9 137.0 ± 12.7 DBP n 2,544 1,800 1,625 1,678 1,866 mmHg (mean ± SD) 89.7 ± 11.7 82.7 ± 10.7 80.7 ± 9.8 79.7 ± 9.6 78.8 ± 9.5 Pulse rate n 2,213 1,566 1,424 1,489 1,673 beats/min (mean ± SD) 72.1 ± 10.2 69.3 ± 9.6 68.5 ± 9.2 68.5 ± 9.0 68.5 ± 8.9 Evening home SBP n 2,546 selleck screening library 1,632 1,477 1,528 1,710 mmHg (mean ± SD) 150.2 ± 17.6
137.9 ± 14.2 134.7 ± 13.0 133.6 ± 12.9 132.7 ± 12.7 DBP n 2,543 1,632 1,477 1,526 1,710 mmHg (mean ± SD) 85.6 ± 12.2 79.0 ± 10.2 77.0 ± 9.8 76.1 ± 9.5 75.8 ± 9.1 Pulse rate n 2,191 1,430 1,310 1,373 1,551 beats/min (mean ± SD) 72.5 ± 9.6 70.1 ± 9.2 69.1 ± 9.0 69.1 ± 8.6 68.9 ± 8.5
DBP diastolic blood PND-1186 price pressure, SBP systolic blood pressure, SD standard deviation Table 5 shows the mean values and changes in morning and evening home BP and pulse rates before and after treatment with the study drug. The morning and evening home SBP/DBP values decreased significantly (p < 0.0001), with the changes being −19.4 ± 17.1/−10.3 ± 10.6 and −16.9 ± 17.0/−9.4 ± 10.6 mmHg, respectively. Pulse rates also decreased significantly (p < 0.0001) both in the morning and in the evening, by −3.5 ± 7.8 and −3.5 ± 7.3 beats/min, selleck chemical respectively. Table 5 Clinical improvement from baseline Parameter Baseline Endpoint Endpoint minus baseline p valuea Morning home SBP n 2,546 2,303 2,303 mmHg (mean ± SD) 156.9 ± 16.1 137.6 ± 13.0 −19.4 ± 17.1 <0.0001 DBP n 2,544 2,300
2,300 mmHg (mean ± SD) 89.7 ± 11.7 79.3 ± 9.7 −10.3 ± 10.6 <0.0001 Pulse rate n 2,213 2,038 1,972 beats/min (mean ± SD) 72.1 ± 10.2 68.6 ± 9.2 −3.5 ± 7.8 <0.0001 Evening home SBP n 2,546 2,108 2,108 mmHg (mean ± SD) 150.2 ± 17.6 133.1 ± 13.0 −16.9 ± 17.0 <0.0001 CYTH4 DBP n 2,543 2,106 2,105 mmHg (mean ± SD) 85.6 ± 12.2 76.0 ± 9.3 −9.4 ± 10 .6 <0.0001 Pulse rate n 2,190 1,880 1,833 beats/min (mean ± SD) 72.5 ± 9.6 69.1 ± 8.6 −3.5 ± 7.3 <0.0001 DBP diastolic blood pressure, SBP systolic blood pressure, SD standard deviation aSignificance of changes from baseline according to paired t-test 3.5 Changes in ME Average and ME Difference The changes in ME average and ME difference after azelnidipine treatment are shown in Table 6. ME average decreased significantly from 153.8 ± 15.5 mmHg at baseline to 135.6 ± 11.9 mmHg at the end of the investigation (endpoint), with the change being −18.1 ± 15.6 mmHg (p < 0.0001).